-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
[Pharmaceutical Network Pharmaceutical Stock Market] According to news on January 18, the biopharmaceutical sector is trending strongly.
In terms of individual stocks, Nuohui Health rose by more than 20%, Ascletis Pharmaceuticals rose by more than 11%, and Tengsheng Bo Pharmaceutical rose by nearly 6%.
In addition, Kintor Pharmaceuticals, Peijia Medical, Qiming Medical, etc.
have also followed suit
.
Nuohui Health rose by more than 20%.
Among them, Hong Kong stock Nuohui Health rose by more than 20%.
As of the close of January 17, Nuohui Health rose nearly 34%, and the current total market value reached 13.
601 billion
.
According to the data, Nuohui Health was established in 2015.
It is a bio-tech company focusing on early screening of high-incidence cancer at home in China.
It aims to promote the innovation of cancer screening technology and accelerate the popularization of cancer screening technology in China
.
On February 18, 2021, Nuohui Health was successfully listed on the Hong Kong Stock Exchange
.
At present, NovoHealth's colorectal cancer screening products (Changweiqing® and Pupu Tube®) and Helicobacter pylori detection products (Pylori Tube®) have been approved and officially commercialized
.
In addition, the company has three pipelines of products in development suitable for liver, cervical and nasopharyngeal cancer screening
.
The company holds worldwide property rights to all of its marketed and pipeline products
.
Nuohui Health has a 100,000-level clean production workshop that complies with ISO13485 and ISO9001 international certification standards, and third-party medical testing laboratories have obtained relevant international standard quality system certification
.
The three laboratories in Beihang, Guangzhou and Guangzhou hold a practicing license, with an annual testing capacity of 2 million, and extensive cooperation with hundreds of hospitals, medical examination institutions, insurance companies, pharmacies and online channels
.
In terms of news, the Helicobacter pylori consumer self-testing product of NovoHealth has been launched for the first time, and it has been launched on e-commerce platforms such as JD.
com, Akcome, Meituanbuyao, and Tmall
.
At present, Youyou Tubes are only sold in mainland China, and overseas markets are temporarily unavailable.
.
It is reported that since the first release on January 18, all sales platforms will provide a subsidy of 10 yuan for each Youyou Tube, with a limited-time discount price of 139 yuan
.
From 9:00 on January 21, 2022, the retail guide price of Youyou Tube will be restored to 149 yuan
.
Ascletis Pharmaceuticals rose more than 11% Ascletis Pharmaceuticals opened higher by more than 9%, and rose by more than 11% during the session.
It is currently at HK$5.
78, temporarily recording seven consecutive gains, with an increase of more than 63% in the range, and the new total market value is HK$6.
4 billion
.
Ascletis is a biotechnology company dedicated to addressing unmet medical needs in three major areas: antiviral, cancer and fatty liver disease
.
In the news, Ascletis announced on January 17 that the company's PD-L1 monoclonal antibody ASC22 (envolimumab) has been approved by the US FDA to conduct clinical trials, and clinical trials on chronic hepatitis B patients will be launched in the United States.
, and launched a global development program
.
ASC22 is a First-in-Class subcutaneous PD-L1 antibody for functional cure of chronic hepatitis
B.
According to the relevant clinical research data published by the researchers at the 2021 Liver Congress, the interim results of a domestic phase 2b study showed that in subjects with a baseline hepatitis B surface antigen (HBsAg) level ≤500 IU/mL, about 19% (3/16) of subjects achieved HBsAg clearance, while no subjects in the placebo group achieved HBsAg clearance, and no rebound was seen after ASC22 was discontinued, and these subjects showed functional recovery.
Sexual Healing
.
The company has announced that the ASC22 phase 2a clinical trial and phase 2b trial for functional cure of HBV have been selected into the best abstract of the 2021 Liver Beauty Association.
Research is highly rated
.
As of November 8, 2021, Ascletis Pharma has obtained exclusive global rights to develop and commercialize ASC22 from Suzhou Corning Jereh for the treatment of all viral diseases including hepatitis
B.
Worldwide sales of ASC22 in all viral disease areas are attributed to Ascletis
.
In terms of individual stocks, Nuohui Health rose by more than 20%, Ascletis Pharmaceuticals rose by more than 11%, and Tengsheng Bo Pharmaceutical rose by nearly 6%.
In addition, Kintor Pharmaceuticals, Peijia Medical, Qiming Medical, etc.
have also followed suit
.
Nuohui Health rose by more than 20%.
Among them, Hong Kong stock Nuohui Health rose by more than 20%.
As of the close of January 17, Nuohui Health rose nearly 34%, and the current total market value reached 13.
601 billion
.
According to the data, Nuohui Health was established in 2015.
It is a bio-tech company focusing on early screening of high-incidence cancer at home in China.
It aims to promote the innovation of cancer screening technology and accelerate the popularization of cancer screening technology in China
.
On February 18, 2021, Nuohui Health was successfully listed on the Hong Kong Stock Exchange
.
At present, NovoHealth's colorectal cancer screening products (Changweiqing® and Pupu Tube®) and Helicobacter pylori detection products (Pylori Tube®) have been approved and officially commercialized
.
In addition, the company has three pipelines of products in development suitable for liver, cervical and nasopharyngeal cancer screening
.
The company holds worldwide property rights to all of its marketed and pipeline products
.
Nuohui Health has a 100,000-level clean production workshop that complies with ISO13485 and ISO9001 international certification standards, and third-party medical testing laboratories have obtained relevant international standard quality system certification
.
The three laboratories in Beihang, Guangzhou and Guangzhou hold a practicing license, with an annual testing capacity of 2 million, and extensive cooperation with hundreds of hospitals, medical examination institutions, insurance companies, pharmacies and online channels
.
In terms of news, the Helicobacter pylori consumer self-testing product of NovoHealth has been launched for the first time, and it has been launched on e-commerce platforms such as JD.
com, Akcome, Meituanbuyao, and Tmall
.
At present, Youyou Tubes are only sold in mainland China, and overseas markets are temporarily unavailable.
.
It is reported that since the first release on January 18, all sales platforms will provide a subsidy of 10 yuan for each Youyou Tube, with a limited-time discount price of 139 yuan
.
From 9:00 on January 21, 2022, the retail guide price of Youyou Tube will be restored to 149 yuan
.
Ascletis Pharmaceuticals rose more than 11% Ascletis Pharmaceuticals opened higher by more than 9%, and rose by more than 11% during the session.
It is currently at HK$5.
78, temporarily recording seven consecutive gains, with an increase of more than 63% in the range, and the new total market value is HK$6.
4 billion
.
Ascletis is a biotechnology company dedicated to addressing unmet medical needs in three major areas: antiviral, cancer and fatty liver disease
.
In the news, Ascletis announced on January 17 that the company's PD-L1 monoclonal antibody ASC22 (envolimumab) has been approved by the US FDA to conduct clinical trials, and clinical trials on chronic hepatitis B patients will be launched in the United States.
, and launched a global development program
.
ASC22 is a First-in-Class subcutaneous PD-L1 antibody for functional cure of chronic hepatitis
B.
According to the relevant clinical research data published by the researchers at the 2021 Liver Congress, the interim results of a domestic phase 2b study showed that in subjects with a baseline hepatitis B surface antigen (HBsAg) level ≤500 IU/mL, about 19% (3/16) of subjects achieved HBsAg clearance, while no subjects in the placebo group achieved HBsAg clearance, and no rebound was seen after ASC22 was discontinued, and these subjects showed functional recovery.
Sexual Healing
.
The company has announced that the ASC22 phase 2a clinical trial and phase 2b trial for functional cure of HBV have been selected into the best abstract of the 2021 Liver Beauty Association.
Research is highly rated
.
As of November 8, 2021, Ascletis Pharma has obtained exclusive global rights to develop and commercialize ASC22 from Suzhou Corning Jereh for the treatment of all viral diseases including hepatitis
B.
Worldwide sales of ASC22 in all viral disease areas are attributed to Ascletis
.
